Blue Earth Diagnostics

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 1 drug with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

1 drugs in development

Preclinical1

By Therapeutic Area

top 1

Oncology

1100%

R&D Momentum

38/100

Pipeline Velocity

15/100

Trial Completion Rate

100/100

Pipeline Concentration

100/100

Pipeline Freshness

97/100

Activity

Recent Activity

Last 14 days

Sep 16, 2026

Recruiting

A Phase 2 Study of [68Ga]BED003 for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

Sep 9, 2026

Recruiting

The Impact of Fluciclovine (18F) PET on the Management of Participants With Prostate Cancer Following Negative or Equivocal PSMA PET Imaging at the Time of Biochemical Recurrence

Earlier

Jul 14, 2026TrialIntrapatient Comparison of Urinary Radioactivity Following Piflufolastat (18F) and Flotufolastat (18F) PET in Men With Low PSA Biochemical Recurrence of Prostate Cancer Following Radical Prostatectomy

Jun 24, 2026TrialA Phase 1/2 Study of [18F]FPyQCP for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications

May 25, 2023FDAPosluma — POSLUMA

Oct 26, 2020TrialStudy to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases

Aug 31, 2020TrialStudy to Establish Image Interpretation Criteria for 18F Fluciclovine PET in Detecting Recurrent Brain Metastases (PURSUE)

May 4, 2020TrialImaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence

2 more events

Mar 2, 2020TrialImaging Study to Investigate the Safety and Diagnostic Performance of rhPSMA 7.3 (18F) in Newly Diagnosed Prostate Cancer.

Jun 11, 2019TrialAssessing Radio-hybrid Prostate Specific Membrane Antigen (rhPSMA-7.3) (18F) in Healthy Volunteers and Subjects With Prostate Cancer

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

2 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Posluma4 patentsAug 23, 2038 Posluma2 patentsNov 27, 2041

Pipeline

Drug Pipeline

Indication

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Oncology

Colorectal Cancer

FPyQCP

Oncology

Colorectal Cancer

FPyQCPPreclinical

Regulatory

Regulatory Timeline

19821 event

FDAJan 1

Inulin And Sodium Chloride — INULIN AND SODIUM CHLORIDE

Application NDA002282 (NDA)

20231 event

FDAMay 25

Posluma — POSLUMA

Application NDA216023 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)